Annette M. Staiger - Concepedia

Author

Annette M. Staiger

Also Known As

A M Staiger, A Staiger, A. M. Staiger, A.M. Staiger, Annete Staiger, Annette M Staiger, Annette M. Staiger, Annette Staiger, Staiger, Annette M., the Emed Demonstrator Project

Publications

4.9K

Citations

H-Index

Concepts

All Affiliations

Robert Bosch Hospital Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology Comprehensive Cancer Center Mainfranken University of Würzburg University of Tübingen

About

Annette M. Staiger is an author at Robert Bosch Hospital specializing in medicine, pathology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	15	3.2K
2	Cell Biology	6	6	2.1K
3	Engineering	1	1	18
4	Health Sciences	1	1	23
5	Natural Sciences	1	1	119

Annette M. Staiger

Publications

4.6K

Citations

H-Index

Page 1

	Year	Citations
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes Bjoern Chapuy, Chip Stewart, Andrew Dunford, Nature Medicine Hematological MalignancyLymphoid NeoplasiaMolecular SubtypesImmunologyPathology	2018	1.9K
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry Alessandro Pastore, Vindi Jurinović, Robert Kridel, The Lancet Oncology Hematological MalignancyLymphoid NeoplasiaMedicineImmunologyFollicular Lymphoma	2015	608
High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology David W. Scott, Rebecca L. King, Annette M. Staiger, Blood	2018	236
Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy Vindi Jurinović, Robert Kridel, Annette M. Staiger, Blood	2016	226
Clinical Impact of the Cell-of-Origin Classification and the <i>MYC</i> / <i>BCL2</i> Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group Annette M. Staiger, Marita Ziepert, Heike Horn, Journal of Clinical Oncology	2017	214
Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes Matthias Pfeifer, Bing Zheng, Tabea Erdmann, Leukemia Lymphoid NeoplasiaMalignant Blood DisorderImmunologyPathologyAutoimmunity	2015	149
Chromatin conformation analysis of primary patient tissue using a low input Hi-C method Noèlia Díaz, Kai Kruse, Tabea Erdmann, Nature Communications Low AmountsMolecular BiologyHi-c LibrariesChromatin Conformation AnalysisEpigenetics	2018	119
Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL Tabea Erdmann, Pavel Klener, James T. Lynch, Blood	2017	103
<i>TP53</i> mutation and survival in aggressive B cell lymphoma Thorsten Zenz, Markus Kreuz, Maxi Fuge, International Journal of Cancer Hematological MalignancyTumor BiologyLymphoid NeoplasiaTp53 MutationElderly Patients	2017	95
Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma Marco Fangazio, Erik Ladewig, Karen Gomez, Proceedings of the National Academy of Sciences	2021	86

Page 1